drugset / Trial / NCT05719701
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed and/or refractory multiple myeloma.
Timeline
- Start
- 2023-03-29
- Primary completion
- 2025-07-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ICP-490 | Unknown | — | — |
| Background | Dexamethasone | Small molecule | — | Oral |